January 1 - September 30, 2022

The third quarter in figures

• Net sales amounted to TSEK 4,941 (2,982), +66%.
• The loss after tax amounted to TSEK 8,765 (8,622).
• The loss per share amounted to SEK 0.13 (0.13).
• The cash flow from current operations was negative in the amount of TSEK 9,718 (9,156).
• The gross margin reached 58,4% (63.3%).
• Electrode sales volume increased by 28% and reached 10,592 (8,304) units. Repeat sales of electrodes to existing customers increased by 34%.

January - September in figures

• Net sales amounted to TSEK 12,927 (7,802), +66%.
• The loss after tax amounted to TSEK 27,713 (27,926).
• The loss per share amounted to SEK 0.40 (0.46).
• The cash flow from current operations was negative in the amount of TSEK 29,783 (27,792).
• The gross margin reached 63.3% (57.8%).
• Electrode sales volume increased by 39% and reached 30,172 (21,768) units. Repeat sales of electrodes to existing customers increased by 45%.

Important events during the quarter

• Overall sales increased by 66% (+55%, before currency effects). The sales in the important US market increased within the area of skin cancer by 279% (in local currency by 209%). Sales in Germany increased by 58% (50% in local currency).
• FDA expert panel in line with SciBase position to keep stringent approval level for all new skin lesion analyzers in the US.

• Top line results presented that demonstrated the detrimental effects of common detergents on the health of the skin barrier in mice were presented at the World Immune Regulation Meeting (WIRM) in Davos, Switzerland. The study, which is not yet published, was performed by SIAF (CH), CK-CARE (CH), SciBase (SE) and the Sean N. Parker Allergy and Asthma research institute at Stanford (US). The study demonstrates that household laundry detergents disrupt the skin barrier integrity in mice.

Important events after the end of the     period

• Collaboration agreement signed with Johnson & Johnson Consumer Health to develop a skin barrier screening product for infants.

• New study shows Nevisense significantly improves US clinician’s pigmented skin lesion decision-making beyond dermoscopy.

• New article published at nature.com that discusses EIS as a potential clinical measure of skin barrier integrity.

• A nominating committee for the Annual General Meeting in 2023 was appointed.

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on November 10, 2022.

This report has been comprehensively reviewed by the Company’s auditors.

Contact person:

Michael Colérus, CFO, +46 70 341 34 72

For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]

Certified Advisor (CA):

Vator Securities

Tel: +46 8 580 065 99

Email: [email protected]

About SciBase and Nevisense
SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase’s products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase’s technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.  All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases

STOCKHOLM, SWEDEN, - December 15, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that SciBase has received an order for skin barrier assessment products to be included  in one of the world's largest cohort studies - The ORIGINS Project, which is a collaboration between Joondalup Health Campus and Telethon Kids Institute.  SciBase will supply Nevisense, Nevisense Go and electrodes to follow up to 1,000 of the 10,000 children included in the project. Of key interest is the development and progression of atopic dermatitis and the project is intending to utilise the Nevisense system to assess skin integrity in this context.

The ORIGINS Project follows the progress of pregnant women, their partners and babies for the first five years of the baby's life, and beyond, based on an increasing understanding that an individual's lifetime health and disease may be programmed at a very early stage - even while a child is still in the womb. The project is collecting detailed information on how a child's early environment and parents' physical health and genetics influence the risk of a wide range of diseases and conditions such as asthma, eczema, food allergies, hay fever, diabetes, obesity and neuro-developmental challenges.

"Being able to measure the skin barrier and detect early signs of eczema in our ORIGINS children will allow parents to access early intervention and hopefully reduce the severity of this condition," ORIGINS Biobank Manager, Dr Nina D'Vaz said. "We have been able to purchase the Nevisense with generous support from SciBase along with a grant from the Telethon Channel 7 Trust, a significant fundraising organisation in Western Australia, and we are so grateful."

"There is a growing acceptance of the potential of our Electrical Impedance Spectroscopy (EIS) technology to evaluate the skin barrier of infants and that this can provide valuable insights and diagnostic opportunities.The ORIGINS project is a fascinating project, and we welcome the opportunity to collaborate with them and be a part of it. Nevisense and EIS will follow the development of atopic dermatitis through measurements of the skin barrier in children. The measurements will help us develop and improve our AI-algorithms even further with the goal of delivering better, personalized treatments. We see this project as yet another important step in shaping a future where medical technology is accessible, non-invasive, and personalized", says Simon Grant CEO SciBase.

For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]

Certified Advisor (CA):.

Vator Securities

Tel: +46 8 580 065 99

Email: [email protected]

About SciBase and Nevisense
SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.  All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases

As the end of 2022 approaches, I'd like to take the opportunity to thank you all for your support for SciBase and review some of the highlights of an extremely eventful year.

2022 has been a breakthrough year for SciBase. We have seen impressive sales growth in key markets, important progress in the US and the establishment of our third application segment skin barrier in a year capped off by the signing of our agreement with J&J Consumer.

Probably the most pleasing single aspect of 2022 has been the considerable increase in the usage of our test by clinicians. We are averaging around 10,000 tests per quarter, which is more than 50% up on 2021. There have been several factors contributing to the growth

1. New customer growth. We saw a 50+% increase in the number of new customers compared to 2021, and a resurgence in the number of customers purchasing multiple units.
2. Our new NMSC application is now installed at about 50% of our German sites. The availability of NMSC has helped both drive new system sales and test usage.
3. Increased market presence. Our German and US sales teams both did a fantastic job in 2022 supporting customers, Marketing-wise we saw a successful return to in-person congresses, we launched a new expanded digital platform in Europe and we updated our positioning in the US.  

We have seen good momentum this year, starting in Q1 with a price increase in Europe that, combined with the 'end' of Covid, appeared to `kick-start' a year of several sales records. We saw our largest ever electrode order ever of over 60 €k from a single clinic. 

US sales growth and traction has also been very good, albeit from relatively low levels. The feedback we have received in general and that I have personally experienced from clinicians during 2022 confirms for me the broad need for Nevisense in the US. With 6-7,000 potential customers and high numbers of patients per clinic, the potential is clear.

We saw an increase in sales during the first three quarters of more than 290%, concentrated in two key regions - Florida and the North-East. Our key US objective is to secure broad reimbursement coverage and overall the progress has been good, with a second Medicare Administrative Contractor Novitas (covering the central US and mid-Atlantic regions) assigning payment to our test. There are many steps in the process and while progress with payer decisions has been slower than we had hoped, we await payment level updates around the end of the year.

Even with the reimbursement decision delays, we believe that our US penetration progress has been both positive and cost-effective.  We look forward to a broader collaboration with our key US partner ADCS, while expanding geographically through further agreements with large dermatology practice groups. We remain the only product approved for point-of-care melanoma detection in the US and believe that the regulatory and clinical evidence requirements continue to provide an important barrier to any competitors wishing to enter this market.

In many ways, 2022 was the year that the broad potential of our new skin barrier application became apparent. We have known for some time that there is considerable interest from researchers and Industry. We know our platform of Electrical Impedance Spectroscopy and AI can be applied clinically in the field, having performed over 150,000 patient tests. We also know that we offer unique value when it comes to our ability to investigate the skin barrier.  We have named our product for this application Nevisense AD (for atopic dermatitis), based on our Nevisense Go platform. Within this space we are focusing on three specific clinical applications where we see a clear path to market and where there is interest from both researchers and industry:

1.  Infant AD prediction- strategic collaboration with J&J Consumer Health
2. Objective AD Assessment and management - imminent study start, US
3. In-home AD flare prediction and management - study ongoing in Germany

Research interest has continued to grow, as illustrated recently in our inclusion in the very large Origins study in Perth, Australia. With now over 20 studies either ongoing or just about to start we know that there is a significant research market for this application.The real scale of the skin barrier opportunity is however linked to clinical and consumer use of our technology. Our three indication studies within atopic dermatitis (eczema) all represent significant markets with unique clinical value and we believe that two of the three indications can lead to products with broad consumer potential.

To reach an agreement with J&J Consumer Health to partner in the development of an infant prediction screening product for AD was undoubtedly one of the highlights of the year. The goal is a product that can be used in the home. The value for a broad population of patients and parents of such a product would be considerable and the commercial potential for SciBase obvious. We look forward very much to that project, and to securing further Industry collaborations within skin barrier.  

In terms of financial performance, we have seen several sales records this year and we have also achieved improved levels of gross margin. The operations team have delivered some exceptional improvements this year, including our first ever quarter with a gross margin above 70%, partly driven by increased prices. Our spending levels are slightly up on 2021, but with Germany being profitable as a market, our investment continues to be concentrated on the increased US marketing and development of the new applications, especially skin barrier.

All in all, it has been a really successful year for SciBase and I am very proud of the progress the team have delivered. I'd like to thank you again for your interest in SciBase during 2022 and the team wishes you all a very Merry Christmas, and a Happy New Year as we look forward to 2023. 

For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]

Certified Advisor (CA):.

Vator Securities

Tel: +46 8 580 065 99

Email: [email protected]

About SciBase and Nevisense
SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.  All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases

STOCKHOLM, SWEDEN, - October 27, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a recently published article in the journal "Molecular Psychiatry", a part of Nature, named "Ectodermal origins of the skin-brain axis: a novel model for the developing brain, inflammation, and neurodevelopmental conditions"  discusses that EIS may represent an alternate clinical measure of skin barrier integrity that may function as a surrogate for neurodevelopmental divergence.

The article describes Electrical impedance spectroscopy (EIS) as a recently emerged promising alternative measurement of skin barrier function. EIS is a non-invasive indicator of epidermal integrity, rapidly measuring the skin's resistance to the flow of alternating imperceptible currents. Considering the likely differences in cell size and orientation between typical and abnormal skin, EIS has been suggested as a useful proxy for disease status. Currently, EIS has been observed to successfully differentiate between healthy, lesional and non-lesional skin in adults with AD, with these readings inversely correlating to TEWL.

In the article the authors hypothesize: "In this paper, we propose a novel hypothesis, that there is an antenatal link between skin and neurodevelopment, partially underpinned by the tissue's shared ectodermal origin with common molecular factors. Additionally, we evaluate postnatal mediators of this skin-brain co-vulnerability, considering the role of epidermal keratinocytes and the cutaneous microbiota in cortical development. Accordingly, we hypothesize that skin barrier integrity may represent an accessible and novel biomarker to aid in the early detection of neurodevelopmental divergence.  We further propose that skin barrier integrity may play a crucial role in mediating the relationship between environmental triggers of infection, immune processes, and neurodevelopment, with potential to reduce the impact of such environmental triggers by improving skin barrier integrity".

The article is available through the following link:

https://www.nature.com/articles/s41380-022-01829-8

"This study shows the increasing interest in EIS and Nevisense and that it can become a very useful clinical measure in the management of different diseases when looking at skin barrier integrity. Previous studies have already shown that Nevisense can discriminate between patients with and without atopic dermatitis through non-lesional skin measurements and this has created the basis for the interest we see as EIS has the potential to track improvement after therapy. We believe that Nevisense and EIS have the potential to become a standard of care in this space and a very significant opportunity for SciBase", says Simon Grant, CEO of SciBase.

For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]

Certified Advisor (CA):

Vator Securities

Tel: +46 8 580 065 99

Email: [email protected]

About SciBase and Nevisense
SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.  All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases

November 7, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that it has signed an agreement with Johnson & Johnson Consumer Inc. to collaborate on the development of a unique AI-based screening tool to predict the development of a common type of eczema called atopic dermatitis in infants.

The goal of the collaboration is to develop and validate an AI-based solution that detects skin barrier dysfunction and may be able to predict an infant’s risk of developing atopic dermatitis. The method will be based on SciBase’s Electrical Impedance Spectroscopy (EIS) technology and specifically for the portable Nevisense Go device.

The collaboration will start immediately and will run for two years and includes supporting a study at several hospitals in Switzerland with Dr Caroline Roduit as Principal Investigator.  Dr Roduit commented:

‘’I work every day with the management of different allergic diseases in children, and it is a growing problem. Allergic diseases have a natural progression with atopic dermatitis being the first to manifest, often already in infancy, followed by other allergic diseases, such as food allergy and allergic asthma. The ability to identify these children early, will help to develop preventive strategies for allergic diseases, and Nevisense is an extremely promising method that has potential for early prediction of those children.”
 

Skin barrier assessment is a new application for SciBase’s EIS technology and this collaboration represents one of the three most promising new clinical indications.

“This project is a milestone for SciBase. It is our vision that Nevisense Go will become the standard of care for this indication. Twenty percent of children develop atopic dermatitis and the ability to predict which children are at high risk could significantly expand the development and use of prophylactic treatments.
The promise of the test is that it is non-invasive and can be used widely - in this study the test will be performed using Nevisense Go in the home of the infant. If successful, the combination of ease and unique predictive information of the test could translate into broad adoption and open a significant consumer market for SciBase. We see the collaboration as an important step in shaping a future where medical technology is accessible, non-invasive, and personalized.”, says Simon Grant CEO SciBase.
 

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 16.30 CET on November 7, 2022.

For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]

Certified Advisor (CA):

Vator Securities

Tel: +46 8 580 065 99

Email: [email protected]

About SciBase and Nevisense
SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase’s products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase’s technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.  All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases

STOCKHOLM, SWEDEN - November 8, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced on Monday November 7 that it has initiated a collaboration with Johnson & Johnson Consumer Health Inc. to develop  a unique AI-based screening tool to predict the development of a common type of eczema called atopic dermatitis in infants.

Link to press release from November 7th: http://investors.scibase.se/en/scibase-announces-collaboration-to-detect-skin-barrier-dysfunction-in-infants

Simon Grant, CEO of SciBase comment on the skin barrier segment and the collaboration with Johnson & Johnson Consumer Health Inc. can be found through the link below:

 Link to CEO comment

For more information around skin barrier and SciBase: https://barrier.scibase.com/

For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]

Certified Advisor (CA):

Vator Securities

Tel: +46 8 580 065 99

Email: [email protected]

About SciBase and Nevisense
SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.  All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases

STOCKHOLM, SWEDEN - November 8, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders is pleased to invite investors, analysts and media to a webinar on November 10 at CET 11.00 - 12.00. The event will only be digital.

The focus will be on SciBase's recently announced collaboration with Johnson & Johnson Consumer Health to develop a unique AI-based screening tool to predict the development of a common type of eczema known as atopic dermatitis in infants. SciBase CEO Simon Grant will give an in-depth picture of the potential that exists in the skin barrier segment as well as a general update.

Link to the webinar: https://us06web.zoom.us/webinar/register/WN__tjnmigWSDeqGmY4LYbnRg

Agenda for the webinar:

1. Introduction by CEO Simon Grant
2. Background around skin barrier from Professor Cezmi Akdis
3. Presentation by CEO Simon Grant
4. Q&A

The webinar will be held in English. Participants will be given the opportunity to ask questions during the event via chat. Questions can also be submitted in advance to [email protected].

A recorded version of the webinar will be available on the SciBase website afterwards.

For more information around skin barrier and SciBase: https://barrier.scibase.com/

For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]

Certified Advisor (CA):

Vator Securities

Tel: +46 8 580 065 99

Email: [email protected]

About SciBase and Nevisense
SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.  All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases

STOCKHOLM, SWEDEN, - September 1, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today scientific results that demonstrate the detrimental effects that common detergents can have on the health of the skin barrier. Top line results were presented recently at the World Immune Regulation Meeting (WIRM) in Davos, Switzerland. The study, which is not yet published, was performed by SIAF (CH), CK-CARE (CH), SciBase (SE) and the Sean N. Parker Allergy and Asthma research institute at Stanford (US). The study demonstrates that household laundry detergents disrupt the skin barrier integrity in mice.

The use of professional and household cleaning agents is associated with an increased risk of developing allergic disorders. In line with this, impairment of the epithelial barrier is also associated with the development of allergic disorders.

The aim of the study was to utilize Nevisense and Electrical Impedance Spectroscopy (EIS) to assess the effect of commercially available detergents on the skin barrier of mice. The top line results of the study indicated that:

• Even at very low concentrations household detergents can impact the epidermis integrity, leading to an impaired skin barrier.
• Prolonged exposure to detergent residue in clothes could progressively impair the barrier, leading to a higher risk of allergen sensitization.
• Detergents could also aggravate already existing allergic disorders such as atopic dermatitis, increasing disease severity.
• EIS is a fast and reliable tool for in vivo detection of barrier function with possible applications in dermatological and cosmetic studies.

"Since the 1960's we have seen a pandemic-scale increase in the prevalence of allergic diseases, affecting one billion individuals. This study highlights the risk that laundry detergents are contributing to this development, as further described in our "epithelial barrier hypothesis". We are very encouraged to see that EIS measurements could identify skin barrier impairment at such an early stage and at such low detergent concentrations. EIS provides an increasingly useful tool for such evaluations" said Professor Cezmi Akdis at SIAF (Swiss Institute of Asthma and Allergy Research).

"This is a fascinating study that shows the negative effect of common household detergents on the skin barrier, and though a mouse study, there are clearly implications for the general population. Skin barrier integrity is an important factor in many allergic diseases and EIS measurements of the skin barrier can provide unique and valuable insights in the prevention and management of these diseases. Studies have already shown that Nevisense can discriminate between patients with and without atopic dermatitis through non-lesional skin measurements and has the potential to track improvement after therapy. We believe that Nevisense and EIS have the potential to become a standard of care in this space and a very significant opportunity for SciBase.", says Simon Grant CEO SciBase.

For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]

Certified Advisor (CA):.

Vator Securities

Tel: +46 8 580 065 99

Email: [email protected]

About SciBase and Nevisense
SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.  All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases

Dharminder Chahal (VanHerk Group)

Peter Elmvik (Stockholms Elbolag),

Iraj Arastoupour,

Tord Lendau (Chairman of the Board).

The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding on May 18, 2022.

The Annual General Meeting of SciBase Holding AB (publ) will be held on May 18, 2023 in Stockholm.

Shareholders who wish to have an item considered at the Annual General Meeting can submit a request to the Board to this effect. Such a request for an item to be considered is to be sent to SciBase Holding AB (publ), Att: Chairman of the Board, Box 3337, 103 67 Stockholm, and must have been received by the Board no later than seven weeks before the Annual General Meeting, or otherwise in such good time that the matter, where necessary, can be included in the notice to attend the Annual General Meeting.

Stockholm, October 7, 2022

SciBase Holding AB (publ) 

For more information, please contact:
Tord Lendau, Chairmain of the board, phone +46 (0)70 810 01 67

Michael Colérus, CFO, phone +46 70 341 34 72

Certified Advisor (CA):

Vator Securities

Tel: +46 8 580 065 99

Email: [email protected]

About SciBase and Nevisense
SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase’s products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase’s technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.  All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases

STOCKHOLM, SWEDEN, - October 26, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a new clinical study has been published presenting the improvement that the Nevisense test provides over standard of care visual and dermoscopic evaluation. The article named "Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy" has been published in the journal "Melanoma Research". The study included 231 US Dermatologists making a total of 33.957 biopsy decisions. The study participants showed a statistically significant improvement in correct biopsy decisions beyond their dermoscopic evaluation when integrating the Nevisense result. With Nevisense, Dermatologists identified more melanomas for biopsy; their sensitivity increasing from 85.2% to 91.1%.

The article is available through the following link: https://journals.lww.com/melanomaresearch/Abstract/9900/Electrical_impedance_spectroscopy_significantly.42.aspx

Prof Darrell Rigel, Icahn School of Medicine at Mount Sinai, New York and author of the study commented: "The overall findings from this study demonstrate that the integration of EIS technology into PSL biopsy decisions has the potential to significantly improve the accuracy of lesion selection for biopsy beyond clinical and dermoscopic evaluation alone."

"This is a very important study and result for SciBase as it quantifies the improvement in clinical decision-making possible with Nevisense compared to visual methods that are today considered the standard of care. As expected, the study showed that dermoscopy improved decision making over naked eye assessment, but more importantly it showed that using Nevisense further improved clinician performance by at least as much again. Adding Nevisense clearly resulted in the best clinical management decisions.  This is one of several publications that shows that Nevisense has a significant role in the challenging process for clinicians to identify malignancies", says Simon Grant, CEO of SciBase.

For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]

Certified Advisor (CA):

Vator Securities

Tel: +46 8 580 065 99

Email: [email protected]

About SciBase and Nevisense
SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.  All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases